Avadel Pharmaceuticals (AVDL) Free Cash Flow: 2009-2024
Historic Free Cash Flow for Avadel Pharmaceuticals (AVDL) over the last 16 years, with Dec 2024 value amounting to -$46.9 million.
- Avadel Pharmaceuticals' Free Cash Flow rose 31.72% to -$15.4 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$71.0 million, marking a year-over-year increase of 8.17%. This contributed to the annual value of -$46.9 million for FY2024, which is 63.50% up from last year.
- Per Avadel Pharmaceuticals' latest filing, its Free Cash Flow stood at -$46.9 million for FY2024, which was up 63.50% from -$128.5 million recorded in FY2023.
- Avadel Pharmaceuticals' Free Cash Flow's 5-year high stood at -$46.9 million during FY2024, with a 5-year trough of -$128.5 million in FY2023.
- For the 3-year period, Avadel Pharmaceuticals' Free Cash Flow averaged around -$82.1 million, with its median value being -$71.0 million (2022).
- As far as peak fluctuations go, Avadel Pharmaceuticals' Free Cash Flow crashed by 80.95% in 2023, and later surged by 63.50% in 2024.
- MRY analysis of 5 years shows Avadel Pharmaceuticals' Free Cash Flow stood at -$48.8 million in 2020, then tumbled by 58.37% to -$77.3 million in 2021, then grew by 8.17% to -$71.0 million in 2022, then plummeted by 80.95% to -$128.5 million in 2023, then soared by 63.50% to -$46.9 million in 2024.
- Its last three reported values are -$46.9 million in FY2024, -$128.5 million for FY2023, and -$71.0 million during FY2022.